Pfizer and Glenmark Pharmaceuticals Ltd. have partnered to launch Abrocitinib, a first-of-its-kind oral advanced systemic treatment for adults with moderate-to-severe atopic dermatitis (AD) in India. Pfizer has received marketing authorization for Abrocitinib from the Central Drugs Standard Control Organization (CDSCO) in India and is approved by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulatory agencies. Glenmark and Pfizer will co-market Abrocitinib in India under the brand names JABRYUS® and CIBINQO®, respectively.
This collaboration combines the companies’ expertise to offer a groundbreaking treatment for moderate-to-severe AD, with improved efficacy and oral convenience to patients. Abrocitinib provides rapid itch relief, sustained disease control, and improved quality of life.
Abrocitinib (CIBINQO) is available in over 35 global markets, including the U.S., Japan, and China. Pfizer India’s Country President and Managing Director, Meenakshi Nevatia, believes in abrocitinib’s transformative potential and believes its approval is a milestone in bringing high-quality treatment for moderate-to-severe atopic dermatitis in India.
